



CathRx Ltd
ABN 23 089 310 421
5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

ASX Announcement

8 November 2011

CathRx Receives CE Mark for its Variable Loop Catheter



Cardiac catheter manufacturer CathRx Limited (ASX: CXD) today announced that it has been advised by TÜV Süd that its application for CE Mark of its Variable Loop Catheter has been approved and certification will be provided shortly. Designed for the diagnosis of atrial fibrillation, the Variable Loop Catheter will be the first catheter in the Company's new generation device range which has been designed for re-processing.

CathRx Chief Executive Officer, Jeff Goodman said, "Our new generation platform is designed to take advantage of the rapidly growing market for Catheter re-processing. In the US we have seen increasing levels of interest by major players looking to take a position in the re-processing space. Johnson & Johnson's recent acquisition of SterilMed for a reported ~\$350 million is one such development. While the Variable Loop Catheter is our first device to utilize this new platform it will be followed by a therapeutic/ablation device and others over the next twelve months."

End

About CathRx

CathRx is a medical device company which designs and manufactures reprocessable cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to cost effectively treat patients with speed, safety and precision.

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Cardiologists worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

For further information:

Jeffrey Goodman
CathRx Chief Executive Officer
Telephone: 02 9397 5700

Amanda Wong
CathRx Chief Financial Officer
Telephone: 02 9397 5700